Compare CHEF & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CHEF | BEAM |
|---|---|---|
| Founded | 1985 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Food Distributors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.3B |
| IPO Year | 2011 | 2020 |
| Metric | CHEF | BEAM |
|---|---|---|
| Price | $59.55 | $24.07 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 12 |
| Target Price | ★ $70.33 | $48.09 |
| AVG Volume (30 Days) | 404.5K | ★ 2.2M |
| Earning Date | 10-29-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 55.09 | N/A |
| EPS | ★ 1.73 | N/A |
| Revenue | ★ $4,040,541,000.00 | $55,701,000.00 |
| Revenue This Year | $10.22 | N/A |
| Revenue Next Year | $7.10 | $19.01 |
| P/E Ratio | $35.48 | ★ N/A |
| Revenue Growth | ★ 8.88 | N/A |
| 52 Week Low | $43.83 | $13.53 |
| 52 Week High | $68.94 | $35.25 |
| Indicator | CHEF | BEAM |
|---|---|---|
| Relative Strength Index (RSI) | 48.33 | 52.36 |
| Support Level | $56.47 | $20.23 |
| Resistance Level | $63.36 | $25.56 |
| Average True Range (ATR) | 2.20 | 1.61 |
| MACD | 0.10 | 0.41 |
| Stochastic Oscillator | 44.78 | 72.11 |
The Chefs' Warehouse Inc is a specialty food distributor in metropolitan areas across the United States and Canada. The company's product portfolio is comprised of imported and local specialty food products such as cheese, cooking oils, chocolates, dried food, baking products, meats, and other food products. It operates via one reporting segment called Food Product Distribution. Operations are concentrated on the east, midwest, and west coasts of the U.S. The company provides service to restaurants, clubs, hotels, caterers, schools, bakeries, casinos, and specialty food stores.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.